The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 10, 2018

Filed:

Mar. 30, 2015
Applicant:

Universiteit Antwerpen, Antwerp, BE;

Inventors:

Jurgen Joossens, Zoersel, BE;

Koen Augustyns, Hoogstraten, BE;

Anne-Marie Lambeir, Leuven, BE;

Pieter Van Der Veken, Sint-Katelijne-Waver, BE;

Jeroen Van Soom, Antwerpen, BE;

Viktor Magdolen, Munich, DE;

Assignee:

UNIVERSITEIT ANTWERPEN, Antwerp, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07F 9/6561 (2006.01); C07F 9/40 (2006.01); A61K 49/00 (2006.01); C07F 9/58 (2006.01); C07F 9/655 (2006.01); C07F 9/6553 (2006.01); C07F 9/6509 (2006.01); C07F 9/6558 (2006.01); C12Q 1/37 (2006.01);
U.S. Cl.
CPC ...
C07F 9/6561 (2013.01); A61K 49/0052 (2013.01); C07F 9/4087 (2013.01); C07F 9/588 (2013.01); C07F 9/65515 (2013.01); C07F 9/65583 (2013.01); C07F 9/65586 (2013.01); C07F 9/650988 (2013.01); C07F 9/655345 (2013.01); C12Q 1/37 (2013.01); G01N 2333/96433 (2013.01);
Abstract

The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.


Find Patent Forward Citations

Loading…